Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adaptive Biotechnologies Corporation filings document financial results, governance matters, registered common stock, and material events for a commercial-stage biotechnology issuer. Recent 8-K reports furnish quarterly and annual operating results, press releases, investor presentation materials, and disclosures tied to the company’s MRD business and immune medicine platform.
The company’s proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and related governance disclosures. Other filings identify ADPT common stock listed on Nasdaq and disclose material agreement activity connected to research and development collaborations, including immune medicine and TCR-antigen programs.
Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins reported open-market sales of 386,240 shares of common stock on July 2, 2026. The sales occurred in two blocks at weighted-average prices of $21.74 and $22.45 per share.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026, indicating they were scheduled in advance rather than timed discretionarily. After these sales, he continues to hold a significant direct equity position in the company.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported option exercises and pre-planned share sales. On July 1–2, 2026, Lo exercised stock options covering 75,621 shares of common stock and sold 95,842 shares in open-market transactions at weighted average prices in the low $20s per share.
The filing states these trades were made under a Rule 10b5-1 trading plan adopted on September 15, 2025, indicating they were pre-scheduled. After the transactions, Lo directly held 230,713 shares of common stock, plus 2,500 shares held indirectly through a spouse.
Adaptive Biotechnologies Corp Chief Commercial Officer, MRD, Susan Bobulsky reported an open-market sale of 487 shares of common stock at $22.00 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025, and she continues to hold 406,288 shares directly after the sale.
ADPT: Form 144 notice reporting proposed and recent sales of Common Stock by Harlan Robins. The filing lists multiple grant/award acquisition entries (Restricted Stock Units and Performance Awards) with grant dates from 03/04/2021 through 03/07/2026. It discloses securities sold in the past three months: 100,000 shares on 06/15/2026 (value shown 1,737,460), 6,160 shares on 06/16/2026 (value shown 110,945.91), and 10,000 shares on 04/08/2026 (value shown 148,323.94).
Francis Lo reported proposed dispositions of Common Stock on a Form 144. The notice lists an item described as an Exercise of Stock Options for 179,039 shares dated 07/01/2026 and a grant of 20,221 Restricted Stock Units dated 03/04/2025. The filing also records prior 10b5-1 sales of 39,741 shares on 06/04/2026 for $695,070.09 and 22,564 shares on 04/08/2026 for $339,941.67.
ADPT insider sells shares under a 10b5-1 plan. The filing lists three 10b5-1 dispositions by Susan Bobulsky: 11,000 shares on 06/04/2026, 5,000 shares on 06/11/2026, and 5,000 shares on 06/25/2026, with proceeds shown for each sale in the filing. The filing also lists 487 Restricted Stock Units (03/04/2022).
Adaptive Biotechnologies Corp Chief Commercial Officer for Immune Medicine, Sharon Benzeno, reported a series of option exercises and related stock sales. She exercised options for 114,329 shares of common stock at strike prices between $3.99 and $12.14 per share.
On June 26 and 29, 2026, she sold a total of 165,802 shares in open-market transactions at weighted-average prices of $21.00 and $21.14 per share. After these transactions, she directly holds 221,278 shares of Adaptive Biotechnologies common stock.
The filing notes that all transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Adaptive Biotechnologies Corp Chief Commercial Officer for MRD, Susan Bobulsky, reported an open-market sale of 5,000 shares of Common Stock at $20.50 per share. After this transaction, she directly holds 406,775 shares. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025, indicating it was scheduled in advance.
Adaptive Biotechnologies Corp director Michelle Renee Griffin reported an exercise-and-sale transaction in company stock. On June 25, 2026, she exercised stock options to acquire 52,084 shares of Common Stock at an exercise price of $7.80 per share, then sold 52,084 shares in an open-market transaction at a weighted-average price of $20.18 per share.
The filing notes that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, indicating they were scheduled in advance. Following the transactions, Griffin directly held 15,625 shares of Adaptive Biotechnologies Common Stock.
Sharon Benzeno submitted a Form 144 notice to sell Common Stock. The filing lists proposed sales tied to an exercise of stock options of 101,458 shares (dated 06/29/2026) and to Restricted Stock Units of 51,473 shares (dated 03/04/2026). The filing also reports a 10b5-1 sale of 11,034 shares on 06/26/2026 for $231,716.21. The cover lists 160,044,392 shares outstanding as of 06/29/2026 as a baseline figure.